GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Degree of Financial Leverage

Relay Therapeutics (Relay Therapeutics) Degree of Financial Leverage : -0.89 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Relay Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was -0.89. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Relay Therapeutics's Degree of Financial Leverage or its related term are showing as below:

RLAY's Degree of Financial Leverage is ranked better than
90.41% of 1501 companies
in the Biotechnology industry
Industry Median: 0.96 vs RLAY: -0.89

Relay Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Relay Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Degree of Financial Leverage Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial 32.98 1.08 -0.19 -0.88 0.35

Relay Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 0.35 0.04 0.35 -0.89

Competitive Comparison of Relay Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Relay Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relay Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Relay Therapeutics's Degree of Financial Leverage falls into.



Relay Therapeutics Degree of Financial Leverage Calculation

Relay Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.64 (Mar. 2024) / -2.81 (Mar. 2023) - 1 )/( -369.437 (Mar. 2024) / -345.816 (Mar. 2023) - 1 )
=-0.0605/0.0683
=-0.89***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Relay Therapeutics  (NAS:RLAY) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Relay Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Relay Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Relay Therapeutics (Relay Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Executives
Peter Rahmer officer: See remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Thomas Catinazzo officer: Vice President, Finance C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Donald A Bergstrom officer: See Remarks 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams officer: General Counsel 750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel director, officer: President and CEO C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter officer: See Remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan director 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram director 2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd 10 percent owner 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc 10 percent owner 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver director 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518

Relay Therapeutics (Relay Therapeutics) Headlines

From GuruFocus

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

Insider Alert: An Insider Just Sold Relay Therapeutics Inc Shares

By GuruFocus Research GuruFocus Editor 10-14-2022